KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
1. KALV to report Q1 earnings on Sept. 11 with expected losses. 2. Projected revenue for Q1 is $2.09 million. 3. Company's shares recently fell 2.2% to $15.61. 4. Analysts maintain bullish ratings with price targets up to $28. 5. Orphan designation for Sebetralstat maintained in the EU.